By Counterforce Health Team in Keppra (levetiracetam) —

How to Get Keppra (Levetiracetam) Covered by Aetna CVS Health in California: Complete Prior Authorization Guide

Answer Box: Quick Path to Approval

Keppra (levetiracetam) typically doesn't require prior authorization from Aetna CVS Health in California for generic versions. However, brand-name Keppra may need step therapy approval after trying generic levetiracetam first. If denied, California members can file a free Independent Medical Review (IMR) through DMHC with a 73% success rate for overturning denials.

First steps today:

  1. Check your specific formulary at Aetna's medication finder
  2. If denied, call Aetna at 1-855-582-2025 to request expedited review
  3. Prepare medical necessity documentation showing seizure control needs

Table of Contents

Who Should Use This Guide

This guide helps California residents with Aetna CVS Health coverage who need:

  • Brand Keppra when generic levetiracetam isn't suitable
  • Higher quantities than standard limits
  • Coverage appeals after initial denials
  • Step therapy exceptions for immediate brand access

Expected outcome: With proper documentation, most medically necessary Keppra requests get approved, especially when generic alternatives have failed or caused intolerable side effects.

Member & Plan Basics

Coverage Verification

Before starting, confirm your plan details:

Check This How to Verify Why It Matters
Active coverage Call member services or check online portal Avoid claim delays
Formulary tier Aetna medication finder Determines copay level
Deductible status Review EOB or call member services May affect out-of-pocket costs
Plan type Check ID card for HMO/PPO designation Affects appeal rights
Note: Most Aetna California plans are DMHC-regulated, giving you strong appeal rights through Independent Medical Review.

Current Aetna Policies

According to 2025 Aetna formulary guidelines:

  • Generic levetiracetam: Usually Tier 1 (lowest copay)
  • Brand Keppra/Keppra XR: Often excluded or requires step therapy
  • Preferred alternatives: Carbamazepine, divalproex sodium

Clinical Criteria for Approval

FDA-Approved Indications

Keppra (levetiracetam) is approved for:

  • Adjunctive therapy for partial-onset seizures (≥1 month old)
  • Adjunctive therapy for myoclonic seizures (≥12 years old)
  • Adjunctive therapy for primary generalized tonic-clonic seizures (≥6 years old)
  • Monotherapy for partial-onset seizures (≥16 years old)

Medical Necessity Requirements

For brand Keppra approval, document:

  1. Inadequate response to generic levetiracetam
    • Specific dose tried and duration (minimum 3 months recommended)
    • Seizure frequency before/during treatment
    • Compliance verification
  2. Intolerance to generic formulation
    • Specific side effects experienced
    • How side effects impacted daily function
    • Timeline of symptom onset
  3. Contraindication to alternatives
    • Medical reasons why carbamazepine or divalproex aren't suitable
    • Allergy documentation if applicable

Key ICD-10 Codes

Include appropriate diagnosis codes:

  • G40.909: Epilepsy, unspecified, not intractable
  • G40.001: Localization-related epilepsy, intractable
  • G40.419: Other generalized epilepsy, intractable
  • G40.A19: Absence epileptic syndrome, intractable

Documentation Requirements

Medical Necessity Letter Checklist

Your prescriber should include:

Clinical History:

  • ✓ Epilepsy diagnosis with EEG confirmation
  • ✓ Seizure type and frequency baseline
  • ✓ Previous antiepileptic drugs tried with outcomes
  • ✓ Current seizure control status

Treatment Rationale:

  • ✓ Why brand Keppra is medically necessary
  • ✓ Specific benefits over generic alternatives
  • ✓ Expected treatment outcomes
  • ✓ Monitoring plan

Supporting Evidence:

  • ✓ Recent neurologist notes (within 6 months)
  • ✓ EEG reports showing seizure activity
  • ✓ Medication trial log with dates and outcomes
  • ✓ Side effect documentation for failed generics
Clinician Corner: Reference Aetna's medical necessity criteria which requires "inadequate response, intolerance, or contraindication to a generic anticonvulsant" plus trial of at least one other anticonvulsant.

Submission Process

Contact Information

Submit prior authorization requests via:

Method Details Timeline
Phone 1-855-582-2025 (TTY available) Real-time submission
Fax 1-855-330-1716 24-48 hour processing
Online Availity portal (preferred) Fastest processing
Mail Aetna PA, 1300 E. Campbell Rd., Richardson, TX 75081 5-7 business days

Decision Timelines

  • Standard requests: 72 hours (auto-approved if missed)
  • Urgent/expedited: 24 hours
  • Appeals: 30 days for internal review

Appeals Process in California

California residents have robust appeal rights through the Department of Managed Health Care (DMHC).

Step 1: Internal Appeal with Aetna

  • Timeline: Must file within 180 days of denial
  • Process: Call member services or submit written appeal
  • Decision: 30 days for standard, 72 hours for urgent

Step 2: Independent Medical Review (IMR)

If Aetna upholds the denial:

File IMR with DMHC:

  • Phone: 1-888-466-2219
  • Online: dmhc.ca.gov
  • Cost: Free to patients
  • Timeline: 30 days standard, 3-7 days expedited
  • Success rate: Approximately 73% of denials overturned

Required Documents:

  • Aetna's denial letter
  • Medical records supporting necessity
  • Prescriber's clinical rationale
  • Evidence of failed alternatives
California Advantage: IMR decisions are binding on health plans. If approved, Aetna must authorize coverage within 5 business days or face DMHC fines.

Common Denial Reasons & Solutions

Denial Reason How to Overturn
"Generic available" Document specific intolerance to generic formulation with timeline and symptoms
"Not medically necessary" Provide EEG showing ongoing seizures despite generic treatment
"Quantity limits exceeded" Submit dosing rationale based on weight/seizure frequency with neurologist support
"Step therapy not completed" Document failed trials of required alternatives with dates and outcomes
"Experimental/investigational" Cite FDA approval and official labeling for specific indication

Costs & Patient Assistance

Manufacturer Support

While brand Keppra is no longer marketed in the U.S. by UCB, generic manufacturers may offer:

  • Patient assistance programs for uninsured
  • Copay cards for commercially insured patients
  • Appeals support documentation

California State Resources

  • Covered California: Premium subsidies for exchange plans
  • Medi-Cal: Expanded Medicaid coverage
  • DMHC Help Center: Free appeal assistance at 1-888-466-2219

Alternative Savings

  • GoodRx: Generic levetiracetam under $20 for 60 tablets at many pharmacies
  • Pharmacy discount programs: CVS, Walgreens, and others offer generic savings
  • 90-day supplies: Often reduce per-pill costs

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. Our platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements and appeal processes, significantly improving approval rates for medically necessary treatments.

FAQ

How long does Aetna prior authorization take in California? Standard requests: 72 hours. Expedited: 24 hours. If Aetna misses deadlines, the request is automatically approved.

What if Keppra is non-formulary on my plan? Request a formulary exception with medical necessity documentation. If denied, file an IMR through DMHC for independent review.

Can I request expedited review? Yes, if your doctor certifies that waiting for standard review could seriously jeopardize your health or ability to regain maximum function.

Does step therapy apply if I tried alternatives outside California? Yes, document previous trials from any state. Aetna should honor prior failures regardless of where they occurred.

What happens if my appeal is denied? California residents can file Independent Medical Review (IMR) through DMHC. This external review has a 73% success rate and binding decisions.

Do I need a specialist to prescribe Keppra? No, but neurologist documentation strengthens prior authorization requests, especially for appeals.

Can I appeal quantity limits? Yes, provide clinical rationale for higher doses based on seizure frequency, weight, or therapeutic drug monitoring.

How much does brand Keppra cost without insurance? Brand Keppra is discontinued in the U.S. Generic levetiracetam typically costs under $50 monthly without insurance.

Getting help with complex prior authorizations and appeals can be overwhelming. Counterforce Health streamlines this process by automatically generating evidence-backed appeals that address specific denial reasons and payer policies, helping patients get their medically necessary medications approved faster.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult your healthcare provider for medical decisions and verify current insurance policies with your plan. Coverage policies and procedures may change. For personalized assistance with California insurance appeals, contact the DMHC Help Center at 1-888-466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.